In a CAR-based study, bispecific targeting of IL-13 receptor α2 (IL13Rα2) and human epidermal growth factor receptor 2 (HER2) was able to control glioblastoma for nearly a month whereas single-targeted CAR therapy was ineffective due to antigen escape [46]. The gene discussed is ERBB2; the disease is glioblastoma.